Imatinib Mesylate (Gleevec, STI571) in Combination With Docetaxel (Taxotere) for the Treatment of Advanced, Platinum-Refractory Ovarian Cancer and Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN03-62.
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2016
At a glance
- Drugs Docetaxel; Imatinib
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 May 2009 Planned end date changed from 1 Oct 2005 to 1 Jul 2007 as reported by ClinicalTrials.gov.
- 31 Oct 2007 Status changed from terminated to completed